I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer
Current Breast Cancer Reports · 2019-12 · 11 (4) · 303-310
DOI: 10.1007/s12609-019-00334-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Breast Cancer Reports, online erschienen am 20.11.2019. Verfasst von Haiyun Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Masonic Cancer Center, University of Minnesota, MMC 806, 420 Delaware St SE, Minneapolis, MN 55455, USA. Die Arbeit wurde bisher 163-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE OF REVIEW: The I-SPY 2 trial is an adaptive clinical trial platform designed to improve outcomes in high-risk breast cancer patients by testing new drugs in the neoadjuvant setting. The intent of this review is to discuss background, study structure, innovation, and outcomes of the I-SPY 2 trial. RECENT FINDINGS: I-SPY 2 evaluates new agents combined with standard therapy with pathologic complete response (pCR) as the primary endpoint. I-SPY-2 uses clinical biomarkers to classify breast cancer into 10 subtypes, with Bayesian adaptive randomization to allow individualized patient assignment to therapy arms to maximize treatment effects. A total of 7 drugs have graduated from I-SPY 2. Multiple new agents are currently in active enrollment in I-SPY 2. SUMMARY: I-SPY 2 uses an individualized approach in clinical trial design to improve high-risk breast cancer outcomes. The purpose of this review is to encourage further research and innovation in this area and bring more precise treatment options to breast cancer patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Masonic Cancer Center, University of Minnesota, MMC 806, 420 Delaware St SE, Minneapolis, MN 55455, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Wang, H., & Yee, D. (2019). I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. Current Breast Cancer Reports, 11(4), 303-310. https://doi.org/10.1007/s12609-019-00334-2
Vancouver
Wang H, Yee D. I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. Current Breast Cancer Reports. 2019;11(4):303-310. doi:10.1007/s12609-019-00334-2
BibTeX
@article{Wang2019,
author = {Wang, Haiyun and Yee, Douglas},
title = {I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer},
journal = {Current Breast Cancer Reports},
year = {2019},
volume = {11},
number = {4},
pages = {303--310},
doi = {10.1007/s12609-019-00334-2}
}
EUVIMED